Welcome to our dedicated page for Immutep SEC filings (Ticker: IMMP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Immutep Limited (IMMP) SEC filings page provides access to the company’s regulatory disclosures as a foreign private issuer listed on Nasdaq. Immutep submits current reports on Form 6-K under the Securities Exchange Act of 1934, furnishing investors with official information on clinical progress, regulatory interactions, collaborations and financial updates.
Recent Form 6-K filings include press releases on key milestones such as the global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line non-small cell lung cancer, translational and pathologic response data from the EFTISARC-NEO Phase II trial in soft tissue sarcoma, new data from the AIPAC-003 Phase II breast cancer study, and progress in the IMP761 Phase I program for autoimmune diseases. Other filings report on the successful completion of FDA Project Optimus requirements and agreement on the optimal biological dose for eftilagimod alfa, as well as R&D tax incentive payments from the French government and quarterly activities reports.
Through this page, users can follow how Immutep communicates material developments in its LAG-3–focused pipeline, including oncology and autoimmune programs, to the US market. Each 6-K typically incorporates an exhibit containing the full text of a company announcement, such as clinical trial updates, strategic collaborations like the exclusive licensing agreement with Dr. Reddy’s Laboratories for efti in selected territories, or summaries of cash position and R&D spending.
Stock Titan enhances these filings with AI-powered tools that help readers quickly understand the significance of each document. Summaries highlight the core message of new 6-Ks, while structured views make it easier to compare successive disclosures about the same trial or program. Investors can use this page to stay aligned with Immutep’s official SEC record, track the evolution of its clinical and corporate strategy and reference historical filings for deeper due diligence on IMMP.
IMMUTEP Ltd director Pete A. Meyers filed an initial ownership report showing both ordinary shares and performance rights. He holds 4,052,173 Ordinary Shares directly. In addition, he holds performance rights over blocks of 388,889, 758,631, 650,000, and 650,000 underlying Ordinary Shares at an exercise price of $0.0000 per share.
The footnotes state these performance rights were granted on December 16, 2022 and December 2, 2025. Vesting dates run from October 1, 2026 through December 1, 2029, and each grant is dependent on Mr. Meyers meeting specified vesting conditions, with expiration dates extending to December 2, 2030.
IMMUTEP Ltd Chief Medical Officer Stephan Karel Gerard Winckels filed an initial ownership report showing his equity position. He directly holds 92,935 Ordinary Shares and three blocks of 221,708 performance rights each over Ordinary Shares, with vesting dates in 2026, 2027 and 2028 and an exercise price of $0.0000. The vesting of these performance rights depends on achieving specified key performance indicators and they expire in 2030.
IMMUTEP Ltd director Frederic Joseph Daniel Triebel has filed an initial statement of beneficial ownership. The filing shows direct holdings of Ordinary Shares, including 11,353,764 shares in one entry and 170,610 shares in another, which are represented by American Depositary Shares.
The filing also lists performance rights over Ordinary Shares with a zero exercise price. Footnotes state that blocks of 900,000 performance rights are scheduled to vest on December 1 of 2026, 2027 and 2028, with additional performance rights vesting only if Dr. Triebel meets specified key performance indicators at each applicable vesting date.
IMMUTEP Ltd director Dr. Russell Howard has filed an initial Form 3 showing his equity interests in the company. The filing reports performance rights over 50,000 Ordinary Shares granted on November 23, 2023, which may vest on December 1, 2026 if vesting conditions are met. Additional performance rights granted on December 2, 2025 cover 400,154 Ordinary Shares scheduled to vest on December 1, 2026, and two further tranches of 461,746 performance rights each that may vest on December 1, 2027 and December 1, 2028, all subject to specified vesting conditions. The Form 3 also reports 1,717,977 Ordinary Shares held indirectly through Regulus Star Pty Ltd.
IMMUTEP Ltd Chief Development Officer Christian Mueller filed an initial ownership report showing he directly holds 3,774,048 Ordinary Shares. This Form 3 establishes his baseline equity position as a company officer.
Mueller also holds three tranches of performance rights over 1,400,000 Ordinary Shares in total, each with a zero exercise price. Footnotes state 466,667 performance rights are scheduled to vest on December 1, 2026 and another 466,667 on December 1, 2027, while 466,666 are scheduled to vest on December 1, 2028. Vesting of the latter two tranches depends on him achieving specified key performance indicators at each applicable vesting date.
Immutep Limited provided an update on its first-in-human Phase I trial of IMP761, a first-in-class LAG-3 agonist antibody for autoimmune diseases. The single ascending dose stage in healthy participants has been completed with dosing up to 14 mg/kg, and IMP761 was well tolerated with no dose-limiting toxicities reported.
The trial has now moved into the multiple ascending dose stage to further assess pharmacokinetics and safety, with completion expected in the third quarter of 2026. Early data show a clear immunosuppressive effect in a controlled antigen challenge model, supporting the planned dose levels for a future Phase II trial in patients with autoimmune conditions.
Immutep plans to present Phase I results for IMP761 at the EULAR congress in London on 4 June 2026 at 1:30 pm UK time. IMP761 targets dysregulated self-antigen-specific memory T cells via LAG-3 agonism, aiming to restore immune balance in major autoimmune diseases such as rheumatoid arthritis, Type 1 diabetes, and multiple sclerosis.
Immutep Limited reported that the Independent Data Monitoring Committee for its TACTI-004 Phase III trial in first-line non-small cell lung cancer has recommended discontinuing the study after a planned interim futility analysis. Enrolment will stop and the company will wind down the trial with patient follow up and site close out.
The study tested eftilagimod alfa in combination with pembrolizumab and chemotherapy versus pembrolizumab, chemotherapy and placebo, targeting about 756 patients across more than 150 sites in over 25 countries. Following the discontinuation, Immutep now anticipates its cash runway will extend well beyond its prior Q2 CY2027 guidance and plans to reassess capital allocation once data review is complete.
Immutep Limited reported a half-year loss after tax of A$44.86 million for the period ended 31 December 2025, compared with A$22.38 million a year earlier, as research and development and intellectual property expenses rose to A$46.62 million from A$25.33 million.
Total revenue and other income increased 6% to A$7.74 million, driven by A$4.08 million of license revenue from a strategic collaboration and licensing agreement with Dr. Reddy’s and A$1.93 million of grant income, partly offset by lower interest income and foreign exchange gains.
Net tangible assets per share fell to 6.31 cents from 11.30 cents, and net assets declined to A$98.90 million from A$143.64 million. Immutep ended the half-year with cash and short-term investments of approximately A$99.1 million, which was subsequently boosted by a US$20 million (A$29.9 million) upfront payment from Dr. Reddy’s, taking the pro-forma balance to A$129.3 million.
Operationally, the company advanced its lead immunotherapy eftilagimod alfa (efti) through the registrational TACTI-004 Phase III trial in first-line non-small cell lung cancer, reported encouraging data across multiple oncology trials, and progressed Phase I development of its autoimmune candidate IMP761 while a long-term vendor agreed to defer approximately A$30 million of future Biologics License Application readiness payments by up to 30 months.
Immutep Limited reported that it has reached 50% of the planned patient enrolment in its global TACTI-004 (KEYNOTE-F91) Phase III trial in first-line advanced or metastatic non-small cell lung cancer. The study evaluates eftilagimod alfa (efti) combined with KEYTRUDA (pembrolizumab) and chemotherapy versus KEYTRUDA, chemotherapy and placebo.
The registrational trial has enrolled 378 patients worldwide and plans to enrol approximately 756 patients across more than 150 clinical sites in over 25 countries. A futility analysis is planned for the first quarter of 2026, with completion of patient enrolment targeted for the third quarter of 2026.
Immutep Limited reported a busy quarter highlighted by a major licensing deal and solid cash reserves. The company’s subsidiary signed a strategic collaboration and exclusive license with Dr. Reddy’s for its lead cancer drug eftilagimod alfa (efti) in markets outside North America, Europe, Japan and Greater China, bringing a USD 20 million (~A$30.2 million) upfront payment and eligibility for up to USD 349.5 million in milestones plus royalties.
Immutep advanced multiple trials, including the Phase III TACTI-004 lung cancer study, which had enrolled 289 of 756 patients and completed requirements for a futility analysis planned for Q1 CY2026. Positive data were also reported from the INSIGHT-003 lung, EFTISARC-NEO soft tissue sarcoma, and AIPAC-003 breast cancer studies, while a small urothelial cancer study was discontinued due to recruitment challenges. First-in-human Phase I data for autoimmune candidate IMP761 showed encouraging safety and pharmacodynamic signals.
Financially, Immutep ended 31 December 2025 with about A$99.1 million in cash, cash equivalents and term deposits, plus the January upfront from Dr. Reddy’s for a pro-forma A$129.3 million. Quarterly operating cash outflow was A$9.4 million, supported by a French R&D tax refund and a long-term vendor agreeing to defer roughly A$30 million of BLA-readiness costs by up to 30 months. The company expects current funds to last well into Q2 CY2027 as it continues late-stage development of efti and early-stage work on IMP761.